A Phase 2a Multicenter Randomized Doubleblind Study Evaluating the Efficacy and Safety of Subcutaneously Administered combination therapy in Improving the Signs and Symptoms in Participants with Active Psoriatic Arthritis.

Brief description of study

A Phase 2a, Multicenter, Randomized, Doubleblind Study Evaluating the Efficacy and Safety of Subcutaneously Administered combination therapy in Improving the Signs and Symptoms in Participants with Active Psoriatic Arthritis.


Clinical Study Identifier: s21-00936
ClinicalTrials.gov Identifier: NCT05071664
Principal Investigator: Jose U Scher.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.